CTRI/2011/05/001769已完成3 期
Efficacy and Safety of Epanova® in Severe Hypertriglyceridemia - Evolve
Radiant Development0 个研究点目标入组 332 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 332
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Men or women, ≥18 years of age.
- •2. Serum TG values in the range ≥500 mg/dL and 2000 mg/dL (≥5.65 mmol/L and 22.60 mmol/L)
- •for the average of Visits 2 and 3 (Weeks -2 and -1). Repeat of Visit 3 test is allowed (Visit 3a), and
- •the average of Visit 2 (Week -2) + Visit 3 (Week -1) + Visit 3a (repeat visit) is used as the criterion.
- •3. Body mass index ≥20 kg/m2.
- •4. Untreated dyslipidemia, or use of a statin or cholesterol absorption inhibitor, or their combination, if
- •stable for 6 weeks at Visit 2 (Week -2) and prior to randomization.
- •5. Willing to restrict consumption of fish to no more than twice per week during the study.
- •6. Willingness to maintain current activity level and follow TLC diet.
排除标准
- •1. Allergy or intolerance to omega-3 fatty acids, omega-3-acid ethyl esters, or fish.
- •2. Known lipoprotein lipase impairment or deficiency or apolipoprotein C-II deficiency or familial dysbetalipoproteinemia.
- •3. Unable to discontinue use of omega-3 drugs/supplements at Week -8 (Visit 1)
- •4. Unable to discontinue use of bile acid sequestrants, fibrates or niacin (other than niacin-containing vitamins 200 mg), or any supplement used to alter lipid metabolism, including but not limited to: dietary fiber supplements, red rice yeast supplements, garlic supplements, soy isoflavone supplements, sterol/stanol products, or policosanols at Week -4 (Visit 1)
- •5. Women who are pregnant, lactating, or planning to become pregnant. Women of childbearing
- •potential who are not using acceptable contraceptive methods. A woman is considered of
- •childbearing potential if she is not surgically sterile or is less than 1 year since last menstrual period.Examples of acceptable contraceptive methods include abstinence, intrauterine device (IUD) or double barrier method. Estrogen-containing contraceptives are excluded
- •6. Use of tamoxifen, estrogens or progestins that has not been stable for 4 weeks at Visit 1, or is
- •unstable prior to randomization
- •7. Use of oral or injected corticosteroids or anabolic steroids at Visit 1 or prior to randomization.
- •8. History of pancreatitis.
- •9. History of symptomatic gallstone disease, unless treated with cholecystectomy
- •10. Uncontrolled diabetes (HbA1c ≥9).
- •11. Uncontrolled hypothyroidism or thyroid stimulating hormone (TSH) 5 mIU/L.
- •12. History of cancer (other than basal cell carcinoma) in the past 2 years
- •13. Cardiovascular event (i.e., myocardial infarction, acute coronary syndrome, new onset angina, stroke,transient ischemic attack, unstable congestive heart failure requiring a change in treatment) or revascularization procedure within prior six months at Visit 1, or prior to randomization.
- •14. Use of anticoagulants (e.g. warfarin [Coumadin®], coumarin, heparin, enoxaparin, clopidogrel).
- •15. Presence of an aortic aneurysm or resection of an aortic aneurysm within prior six months at Visit 1, or prior to randomization
- •16. Recent history (within prior six months at Visit 1 or prior to randomization) of significant nephrotic syndrome, pulmonary, hepatic, biliary, gastrointestinal or immunologic disease.
- •17. Poorly controlled hypertension (resting blood pressure ≥160 mm Hg systolic and/or ≥100 mm Hg
- •diastolic) at two consecutive visits prior to randomization at Visit 4
- •18. Any of the following laboratory criteria: serum alanine aminotransferase (ALT) or aspartate
- •aminotransferase (AST) 3x the upper limit of normal (ULN), fasting serum glucose 200 mg/dL,
- •calculated glomerular filtration rate (GFR) 30 ml/min, platelet counts 60 x 109/L, or hemoglobin
- •10.0 g/dL.
- •19. Exposure to any investigational product within 4 weeks prior to Visit 1, or prior to randomization.
- •20. Presence of any other condition the Investigator believes would interfere with the subject?s ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the subject at undue risk
- •21.Recent history (past 12 months) of drug abuse or alcohol abuse
研究者
相似试验
进行中（未招募）
不适用
Efficacy and Safety of Epanova® in Severe Hypertriglyceridemia - EVOLVESevere hypertriglyceridemia defined as serum triglyceride (TG) values =500 and <2000 mg/dL (=5.65 mmol/L and <22.60 mmol/L).MedDRA version: 12.1Level: LLTClassification code 10020870Term: HypertriglyceridemiaEUCTR2010-024064-18-HUOmthera Pharmaceutical Inc.332
尚未招募
3 期
Efficacy and Safety of Epanova® in Severe Hypertriglyceridemiahigh blood level of triglycerids10013317HypertriglyceridemiaNL-OMON35729Omthera Pharmaceuticals, Inc30
进行中（未招募）
不适用
Efficacy and Safety of Epanova® in Severe Hypertriglyceridemia - EVOLVESevere hypertriglyceridemia defined as serum triglyceride (TG) values =500 and <2000 mg/dL (=5.65 mmol/L and <22.60 mmol/L).MedDRA version: 13.1Level: LLTClassification code 10020870Term: HypertriglyceridemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2010-024064-18-DKOmthera Pharmaceutical Inc.332
进行中（未招募）
不适用
Efficacité et sécurité du traitement de l'hypertension artérielle au cours de la pré-éclampsie sévère. Etude préliminaire d'équivalence entre l'Urapidil(Eupressyl*) et la nicardipine(Loxen*)PRE-ECLAMPSIE SEVEREEUCTR2006-005545-11-FRHôpitaux Universitaires de Strasbourg
招募中
不适用
A study to observe the Effects of anti--Hypertensive drugs In pregnant womeCTRI/2018/04/012950B J Medical College and Civil Hospital